Experience with high dose chemotherapy and autologous bone marrow transplantation in testicular cancer

Abstract

Carboplatin based HDCT followed by ABMT produces reasonable response rates (40-60%) and some durable remissions in patients with advanced and cisplatin resistant testicular cancer. Patients eligible for such an approach are those with primary refractory or recurrent disease and low probability for salvage by conventional dose regimens. The use of recombinant human growth factors and peripheral stem cell transplantation will probably reduce the toxicity and mortality of HDCT.